Cositecan
- Generic Name
- Cositecan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N2O4Si
- CAS Number
- 203923-89-1
- Unique Ingredient Identifier
- 24R60NVC41
- Background
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
- Indication
Investigated for use/treatment in brain cancer, lung cancer, and melanoma.
- Associated Conditions
- -
- Associated Therapies
- -
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 509
- Registration Number
- NCT00477282
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 42
- Registration Number
- NCT00358319
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 27
- Registration Number
- NCT00054119
- Locations
- ๐บ๐ธ
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 55
- Registration Number
- NCT00010218
- Locations
- ๐บ๐ธ
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
๐บ๐ธEllis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
๐บ๐ธCCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
Karenitecin in Treating Patients With Recurrent Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00014521
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
๐บ๐ธWinship Cancer Institute of Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.